Relieves inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. ANDA 216625, held by Macleods Pharms. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 216625 (Triamcinolone Acetonide), held by Macleods Pharms, was first approved by FDA on Aug 18, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Triamcinolone acetonide ointment 0.05%, USP is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 18, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.05% · ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
